Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease
Streifler, M.; Vardi, Y.; Kesten, M.; Oberman, Z.; Herzberg, M.
Israel Journal of Medical Sciences 81(5): 597-601
1972
ISSN/ISBN: 0021-2180 PMID: 5042950 Document Number: 54494
Document emailed within 1 workday
Related Documents
Krygowska-Wajs, A.; Szczudlik, A.; Antkiewicz-Michaluk, L.; Romańska, I.; Vetulani, J. 1997: Salsolinol, 3-O-methyl-dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients Neurologia i Neurochirurgia Polska 31(5): 875-885Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Buscaino, G.A.; Sori, A.; Campanella, G. 1972: Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa Revue Neurologique (Paris) 127(2): 301-302
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Feldman, J.M.; Lee, E.M.; Castleberry, C.A. 1987: Catecholamine and serotonin content of foods: effect on urinary excretion of homovanillic and 5-hydroxyindoleacetic acid Journal of the American Dietetic Association 87(8): 1031-1035
Pizzolato, G.; Cagnin, A.; Rossato, A.; Chierichetti, F.; Fabbri, M.; Dam, M.; Ferlin, G.; Battistin, L. 1996: Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. a [123I]IBZM SPET study Advances in Neurology 69: 467-473
Vasil'ev, V.N. 1980: Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients Voprosy Meditsinskoi Khimii 26(6): 782-786
Lipman, I.J.; Papadopoulos, N.M. 1973: Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy Diseases of the Nervous System 34(1): 59-62
Extein, I.; Roth, R.H.; Bowers, M.B. 1974: Accumulation of 3H-homovanillic acid in rabbit brain and cerebrospinal fluid following intravenous 3H-L-dopa Biological Psychiatry 9(2): 161-170
Völler, G. 1970: L-dopa in the treatment of Parkinson's disease Die Medizinische Welt 27: 1267-1268
Lees, A.J. 1986: L-dopa treatment and Parkinson's disease Quarterly Journal of Medicine 59(230): 535-547
Dalle Ore, G.; Bricolo, A.; Robotti, E.; Bazzan, A.; Mazza, C. 1970: The treatment of Parkinson's disease with L-dopa Il Policlinico. Sezione Pratica 77(16): 509-524
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Pendefunda, G.; Pollingher, B.; Stefanache, F.; Gavril, A.; Oprisan, C.; Merling, M.; Nemteanu, E.; Ciunru, M.; Koropitzer, I. 1975: The treatment with L-dopa and amantadine in Parkinson's disease Therapia Hungarica 23(1): 12-16
Figuerido, J.A.; De la Herrán, J. 1970: Personal experience in the treatment of Parkinson's disease with L-Dopa Revista Clinica Espanola 119(6): 555-562
Barbeau, A.; Gillo-Joffroy, L.; Mars, H.; Arsenault, A. 1972: Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602 Revue Canadienne de Biologie 31(Suppl): 169-174
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Broussolle, E. 2000: Dopa-therapy in the treatment of early stage Parkinson's disease Revue Neurologique (Paris) 156(2 Part 2): 91-97